Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNIFER LYNN NASH

Allopathic & Osteopathic Physicians Dermatology

NPI
1518924299
CMS profile
341673
Location
WESTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$805.11

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $805.11 23

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNIFER LYNN NASH

NPI 1518924299 · CMS profile ID 341673

Allopathic & Osteopathic Physicians / Dermatology

WESTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518924299?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNIFER LYNN NASH, NPI 1518924299, CMS profile ID 341673. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518924299?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JENNIFER LYNN NASH, NPI 1518924299, CMS profile ID 341673. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518924299?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JENNIFER LYNN NASH, NPI 1518924299, CMS profile ID 341673, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1518924299?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $805.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mayne Pharma Inc. $14.6412/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705511731 CMS
Janssen Biotech, Inc. $11.3911/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658613749 CMS
Lilly USA, LLC $12.7711/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657885221 CMS
Novartis Pharmaceuticals Corporation $19.0511/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659847091 CMS
EPI Health, LLC $21.6710/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660679221 CMS
AbbVie, Inc. $14.2209/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647964133 CMS
Merz North America, Inc. $121.3408/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689383513 CMS
Merz North America, Inc. $267.9908/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689382233 CMS
DERMIRA, INC. $11.8008/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703882647 CMS
Merz North America, Inc. $24.4908/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689380761 CMS
Novartis Pharmaceuticals Corporation $10.8907/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659847089 CMS
Galderma Laboratories, L.P. $13.5806/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687704729 CMS
AbbVie, Inc. $10.9705/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647964131 CMS
Galderma Laboratories, L.P. $9.3504/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687704727 CMS
Galderma Laboratories, L.P. $76.0904/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687704725 CMS
Galderma Laboratories, L.P. $11.3903/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687704723 CMS
Merz North America, Inc. $8.1503/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689377667 CMS
Merz North America, Inc. $71.6503/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689377669 CMS
Lilly USA, LLC $14.8003/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657881867 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $12.4202/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684595819 CMS
Celgene Corporation $15.4102/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672732183 CMS
Merz North America, Inc. $19.0502/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689371011 CMS
Mission Pharmacal Company $12.0002/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625336945 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $805.11 23
PY2020 $469.87 19
PY2021 $826.06 49
PY2022 $940.34 56
PY2023 $1,456.33 76
PY2024 $1,893.47 104
PY2025 $1,665.20 83

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $243,014.48 48
PY2024 Recipient $1,267.72 7
PY2024 Principal investigator $137,527.38 8
PY2023 Principal investigator $787,642.30 65
PY2022 Recipient $187.10 4
PY2022 Principal investigator $974,316.67 62
PY2021 Recipient $890.12 6
PY2021 Principal investigator $503,922.68 30
PY2020 Principal investigator $730,035.42 59
PY2019 Principal investigator $647,335.59 32

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $4,921.88 12/31/2021 Non-covered Recipient Entity
AVENTIV RESEARCH INC
A Phase 3 Multicenter, Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence No dispute reported 06/30/2026 792489887
Principal investigator 1 ABBVIE INC. $8,200.00 12/03/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines No dispute reported 06/30/2026 792485673
Principal investigator 1 Allergan, Inc. $30,252.75 11/15/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014151
Principal investigator 1 ABBVIE INC. $11,121.70 11/12/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
A Phase 3 Multicenter, Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence No dispute reported 06/30/2026 792482729
Principal investigator 1 ABBVIE INC. $10,000.00 11/04/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
A Phase 3 Multicenter, Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence No dispute reported 06/30/2026 792481401
Principal investigator 1 Allergan, Inc. $4,668.00 10/21/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal GL Only - US/EU No dispute reported 06/30/2026 789014147
Principal investigator 1 Allergan, Inc. $10,054.50 10/21/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal LCL and GL+ LCL - US/EU No dispute reported 06/30/2026 789014149
Principal investigator 1 Allergan, Inc. $29,568.75 10/14/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014145
Principal investigator 1 Allergan, Inc. $200.00 09/23/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014143
Recipient ABBVIE INC. $403.97 09/19/2021 Covered Recipient Physician A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines No dispute reported 06/30/2026 792404359
Recipient ABBVIE INC. $46.67 09/18/2021 Covered Recipient Physician A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines No dispute reported 06/30/2026 792404341
Recipient ABBVIE INC. $55.76 09/18/2021 Covered Recipient Physician A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines No dispute reported 06/30/2026 792404347
Recipient ABBVIE INC. $84.85 09/18/2021 Covered Recipient Physician A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines No dispute reported 06/30/2026 792404353
Recipient ABBVIE INC. $118.30 09/17/2021 Covered Recipient Physician A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines No dispute reported 06/30/2026 792404329
Recipient ABBVIE INC. $180.57 09/17/2021 Covered Recipient Physician A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines No dispute reported 06/30/2026 792404335
Principal investigator 1 Allergan, Inc. $27,322.00 09/14/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014141
Principal investigator 1 Allergan, Inc. $750.00 09/01/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal LCL and GL+ LCL - US/EU No dispute reported 06/30/2026 789014131
Principal investigator 1 Allergan, Inc. $750.00 09/01/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal LCL and GL+ LCL - US/EU No dispute reported 06/30/2026 789014133
Principal investigator 1 Allergan, Inc. $750.00 09/01/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal LCL and GL+ LCL - US/EU No dispute reported 06/30/2026 789014135
Principal investigator 1 Allergan, Inc. $750.00 09/01/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal GL Only - US/EU No dispute reported 06/30/2026 789014137
Principal investigator 1 Allergan, Inc. $750.00 09/01/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal GL Only - US/EU No dispute reported 06/30/2026 789014139
Principal investigator 1 Allergan, Inc. $50,706.25 08/13/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014129
Principal investigator 1 Allergan, Inc. $500.00 08/05/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal GL Only - US/EU No dispute reported 06/30/2026 789014127
Principal investigator 1 Allergan, Inc. $36,617.75 07/13/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014125
Principal investigator 1 Allergan, Inc. $39,178.00 06/15/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014123
Principal investigator 1 Allergan, Inc. $1,703.80 05/28/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal LCL and GL+ LCL - US/EU No dispute reported 06/30/2026 789014119
Principal investigator 1 Allergan, Inc. $2,632.80 05/28/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal GL Only - US/EU No dispute reported 06/30/2026 789014121
Principal investigator 1 Allergan, Inc. $35,447.00 05/13/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014117
Principal investigator 1 Allergan, Inc. $2,508.00 04/22/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal LCL and GL+ LCL - US/EU No dispute reported 06/30/2026 789014115
Principal investigator 1 Allergan, Inc. $51,300.00 04/14/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014113
Principal investigator 1 Allergan, Inc. $26,828.00 03/16/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014111
Principal investigator 1 Allergan, Inc. $6,840.00 03/03/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal GL Only - US/EU No dispute reported 06/30/2026 789014109
Principal investigator 1 Allergan, Inc. $44,013.50 02/17/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014107
Principal investigator 1 Allergan, Inc. $43,234.50 01/20/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Open-label Extension Study No dispute reported 06/30/2026 789014105
Principal investigator 1 Allergan, Inc. $14,478.00 01/18/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal GL Only - US/EU No dispute reported 06/30/2026 789014101
Principal investigator 1 Allergan, Inc. $7,875.50 01/18/2021 Non-covered Recipient Entity
AVENTIV RESEARCH
Ph 3 Pivotal LCL and GL+ LCL - US/EU No dispute reported 06/30/2026 789014103